Treatment Patterns and Outcomes Associated With Palbociclib Plus Letrozole for Postmenopausal Women With HR+/HER2(-) Advanced Breast Cancer Enrolled in an Expanded Access Program

摘要

A retrospective chart review of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer receiving palbociclib in combination with letrozole (as part of an expanded access program) in the United States suggested that most patients derived benefit from this treatment despite having received multiple prior treatment lines for metastatic disease.